Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination

Wang, Miao1; Zhou, Bing1; Fan, Qing1; Zhou, Xinrong1; Liao, Xuejiao1; Lin, Jingyan1; Ma, Zhenghua1; Dong, Jingke1; Wang, Haiyan1; Ge, Xiangyang1; Ju, Bin1,2,4,5; Zhang, Zheng1,2,3,4,5,6

2023-12-31

10.1080/22221751.2022.2151381

EMERGING MICROBES & INFECTIONS   Impact Factor & Quartile

2222-1751

With the ongoing COVID-19 pandemic and the emergence of various SARS-CoV-2 variants, a comprehensive evaluation of long-term efficacy of antibody response in convalescent individuals is urgently needed. Several longitudinal studies had reported the antibody dynamics after SARS-CoV-2 acute infection, but the follow-up was mostly limited to 1 year or 18 months at the maximum. In this study, we investigated the durability, potency, and susceptibility to immune evasion of SARS-CoV-2-specific antibody in COVID-19 convalescents for 2 years after discharge. These results showed the persistent antibody-dependent immunity could protect against the WT and Delta variant to some extent. However, the Omicron variants (BA.1, BA.2, and BA.4/5) largely escaped this preexisting immunity in recovered individuals. Furthermore, we revealed that inactivated vaccines (BBIBP-CorV, CoronaVac, or KCONVAC) could improve the plasma neutralization and help to maintain the broadly neutralizing antibodies at a certain level. Notably, with the time-dependent decline of antibody, 1-dose or 2-dose vaccination strategy seemed not to be enough to provide immune protection against the emerging variants. Overall, these results facilitated our understanding of SARS-CoV-2-induced antibody memory, contributing to the development of immunization strategy against SARS-CoV-2 variants for such a large number of COVID-19 survivors.

SARS-CoV-2 Omicron variants COVID-19 convalescent 2 years after discharge antibody response inactivated vaccines

SCI

English

First ; Corresponding

National Natural Science Foundation of China[82025022] ; National Key Plan for Scientific Research and Development of China["92169204","82002140","82171752","82101861"] ; Guangdong Basic and Applied Basic Research Foundation[2021YFC0864500] ; Science and Technology Innovation Committee of Shenzhen Municipality["2021B1515020034","2019A1515011197","2021A1515011009","2020A1515110656"] ; Shenzhen Natural Science Foundation["JSGG20220226085550001","JSGG20200207155251653","JSGG20200807171401008","JSGG20210901145200002","KQTD20200909113758004"] ; [JCYJ20190809115617365] ; [JCYJ20210324115611032] ; [JCYJ20220530163405012]

Immunology ; Infectious Diseases ; Microbiology

Immunology ; Infectious Diseases ; Microbiology

WOS:000905262700001

TAYLOR & FRANCIS LTD

Web of Science

1.Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Affiliated Hosp 2, Inst Hepatol,Sch Med ,Natl Clin Res Ctr Infect Dis, Shenzhen, Peoples R China
2.Guangdong Key Lab Antiinfect Drug Qual Evaluat, Shenzhen, Peoples R China
3.Chinese Acad Med Sci, Shenzhen Res Ctr Communicable Dis Diag & Treatment, Shenzhen, Peoples R China
4.Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Affiliated Hosp 2, Inst Hepatol,Sch Med ,Natl Clin Res Ctr Infect Dis, Shenzhen 518112, Guangdong, Peoples R China
5.Guangdong Key Lab Anti Infect Drug Qual Evaluat, Shenzhen 518112, Guangdong, Peoples R China
6.Chinese Acad Med Sci, Shenzhen Res Ctr Communicable Dis Diag & Treatment, Shenzhen 518112, Guangdong, Peoples R China

Wang, Miao,Zhou, Bing,Fan, Qing,et al. Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination[J]. EMERGING MICROBES & INFECTIONS,2023,12(1).

Wang, Miao.,Zhou, Bing.,Fan, Qing.,Zhou, Xinrong.,Liao, Xuejiao.,...&Zhang, Zheng.(2023).Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination.EMERGING MICROBES & INFECTIONS,12(1).

Wang, Miao,et al."Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination".EMERGING MICROBES & INFECTIONS 12.1(2023).